OBJECTIVE: To examine the reliability (stability) and sensitivity of the Bristol Rheumatoid Arthritis Fatigue scales (BRAFs) and patient-reported outcome measures (PROMs) developed to capture the fatigue experience. The Multi-Dimensional Questionnaire (BRAF-MDQ) has a global score and four subscales (Physical Fatigue, Living with Fatigue, Cognitive Fatigue and Emotional Fatigue), while three numerical rating scales (BRAF-NRS) measure fatigue Severity, Effect and Coping. METHODS: RA patients completed the BRAFs plus comparator PROMs. Reliability (study 1): 50 patients completed questionnaires twice. A same-day test-retest interval (minimum 60 min) ensured both time points related to the same 7 days, minimizing the capture of fatigue fluctuations. Reliability (study 2): 50 patients completed the same procedure with a re-worded BRAF-NRS Coping. Sensitivity to change (study 3): 42 patients being given clinically a single high dose of i.m. glucocorticoids completed questionnaires at weeks 0 and 2. RESULTS: The BRAF-MDQ, its subscales and the BRAF-NRS showed very strong reliability (r = 0.82-0.95). BRAF-NRS Coping had lower moderate reliability in both wording formats (r = 0.62, 0.60). The BRAF-MDQ, its subscales and the BRAF-NRS Severity and Effect were sensitive to change, with effect sizes (ESs) of 0.33-0.56. As hypothesized, the BRF-NRS Coping was not responsive to the pharmaceutical intervention (ES 0.05). Preliminary exploration suggests a minimum clinically important difference of 17.5% for improvement and 6.1% for fatigue worsening. CONCLUSION: The BRAF scales show good reliability and sensitivity to change. The lack of BRAF-NRS Coping responsiveness to medication supports the theory that coping with fatigue is a concept distinct from severity and effect that is worth measuring separately.
OBJECTIVE: To examine the reliability (stability) and sensitivity of the Bristol Rheumatoid Arthritis Fatigue scales (BRAFs) and patient-reported outcome measures (PROMs) developed to capture the fatigue experience. The Multi-Dimensional Questionnaire (BRAF-MDQ) has a global score and four subscales (Physical Fatigue, Living with Fatigue, Cognitive Fatigue and Emotional Fatigue), while three numerical rating scales (BRAF-NRS) measure fatigue Severity, Effect and Coping. METHODS:RApatients completed the BRAFs plus comparator PROMs. Reliability (study 1): 50 patients completed questionnaires twice. A same-day test-retest interval (minimum 60 min) ensured both time points related to the same 7 days, minimizing the capture of fatigue fluctuations. Reliability (study 2): 50 patients completed the same procedure with a re-worded BRAF-NRS Coping. Sensitivity to change (study 3): 42 patients being given clinically a single high dose of i.m. glucocorticoids completed questionnaires at weeks 0 and 2. RESULTS: The BRAF-MDQ, its subscales and the BRAF-NRS showed very strong reliability (r = 0.82-0.95). BRAF-NRS Coping had lower moderate reliability in both wording formats (r = 0.62, 0.60). The BRAF-MDQ, its subscales and the BRAF-NRS Severity and Effect were sensitive to change, with effect sizes (ESs) of 0.33-0.56. As hypothesized, the BRF-NRS Coping was not responsive to the pharmaceutical intervention (ES 0.05). Preliminary exploration suggests a minimum clinically important difference of 17.5% for improvement and 6.1% for fatigue worsening. CONCLUSION: The BRAF scales show good reliability and sensitivity to change. The lack of BRAF-NRS Coping responsiveness to medication supports the theory that coping with fatigue is a concept distinct from severity and effect that is worth measuring separately.
Authors: Emma Dures; Susan Bridgewater; Bryan Abbott; Jo Adams; Alice Berry; Lance M McCracken; Siobhan Creanor; Sarah Hewlett; Joe Lomax; Mwidimi Ndosi; Joanna Thorn; Marie Urban; Paul Ewings Journal: BMJ Open Date: 2022-07-18 Impact factor: 3.006
Authors: Stephanie Nikolaus; Christina Bode; Erik Taal; Harald E Vonkeman; Cees A W Glas; Mart A F J van de Laar Journal: PLoS One Date: 2015-12-28 Impact factor: 3.240
Authors: Sarah Hewlett; John Kirwan; Christina Bode; Fiona Cramp; Loreto Carmona; Emma Dures; Matthias Englbrecht; Jaap Fransen; Rosemary Greenwood; Sofia Hagel; Maart van de Laar; Anna Molto; Joanna Nicklin; Ingemar F Petersson; Marta Redondo; Georg Schett; Laure Gossec Journal: Rheumatology (Oxford) Date: 2018-02-01 Impact factor: 7.580
Authors: K M Latocha; K B Løppenthin; M Østergaard; P J Jennum; R Christensen; M Hetland; H Røgind; T Lundbak; J Midtgaard; B A Esbensen Journal: Trials Date: 2020-05-29 Impact factor: 2.279
Authors: Eduardo J F Santos; Catia Duarte; José A P da Silva; Ricardo J O Ferreira Journal: Rheumatology (Oxford) Date: 2019-11-01 Impact factor: 7.580
Authors: S Hewlett; N Ambler; C Almeida; P S Blair; E Choy; E Dures; A Hammond; W Hollingworth; J Kirwan; Z Plummer; C Rooke; J Thorn; K Tomkinson; J Pollock Journal: BMJ Open Date: 2015-08-06 Impact factor: 2.692